BioCentury
ARTICLE | Clinical News

MabVax reports Phase Ia data for MVT-5873 in pancreatic cancer

June 9, 2017 7:55 PM UTC

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) reported data from 32 evaluable patients with locally advanced or metastatic pancreatic cancer in an open-label, dose-escalation, U.S. Phase Ia trial showing that IV MVT-5873 (5B1 antibody, HuMab-5B1) led to 1 complete response and 12 cases of stable disease. After one 28-day cycle of treatment, 40% of patients had a sustained reduction in CA19.9 levels of ≥50%. The maximum tolerated dose (MTD) of MVT-5873 was 1 mg/kg given weekly or every 2 weeks. Data were presented at the American Society of Clinical Oncology meeting in Chicago.

The trial is also evaluating MVT-5873 in combination with gemcitabine and Abraxane nab-paclitaxel in newly diagnosed pancreatic cancer patients. The trial’s primary endpoint is evaluating the safety and MTD of MVT-5873 both as monotherapy and in combination with gemcitabine and Abraxane. Secondary endpoints include overall response rate (ORR), duration of response and pharmacokinetics. MabVax plans to report data from the combination arm of the trial this year...